Creating innovative cell-based, gene therapy treatments for rare diseases with few or no treatment options.
Concentrating on cell therapy treatments for serious diseases with high unmet needs, with an initial focus on the eye.
Creating treatments for central nervous system movement disorders and fluency disorders, including Tourette syndrome and childhood-onset fluency disorder (stuttering) in adults.
Evozyne is combining the exquisite complexity of nature with advanced machine learning to create novel proteins with extraordinary impact across a variety of industries.
Commercializing novel treatment options for people living with rare diseases, focusing on the central nervous system including disorders of sleep and wakefulness.
Assisting radiologists to significantly improve clinical diagnosis of breast abnormalities with AI-driven technology.
Developing first in-kind therapies to treat oral premalignant lesions, a high unmet need.
330 N. Wabash
Chicago, IL 60611